Training and Resources

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

KEYTRUDA® (pembrolizumab) in adjuvant renal cell carcinoma (RCC)

For more information about KEYTRUDA in adjuvant RCC:

KEYTRUDA in advanced renal cell carcinoma (aRCC)

Patient assets

To order printed versions of these diaries to your place of work, please contact msdukoncology@msd.com.

Please be aware you should not direct your patient to this website. You should download this diary on their behalf and share it with them as appropriate.

HCP treatment optimisation guide

Your guide to recognising and managing KEYTRUDA® (pembrolizumab) plus KISPLYX® (lenvatinib) adverse events in aRCC

For full information about KEYTRUDA and KISPLYX adverse events, please refer to each product’s individual SmPC

GB-KLR-00098 | Date of Preparation: February 2023

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

For more information about KEYTRUDA in advanced RCC:

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website